evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,667 questions · 21,760 findings · 2,177 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 4,173 · 19.2%GRADE not reported 2,300 · 10.6%Very low 5,276 · 24.2%Low 5,764 · 26.5%Moderate 3,298 · 15.2%High 949 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Lower vs higher cumulative dose dexamethasone regimen

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or cerebral palsy at 1 to 3 years compared with continuous tapered dexamethasone regimen (moderate certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with continuous tapered dexamethasone regimen (low certainty).

1 finding from 1 review

Lower vs higher cumulative dose dexamethasone regimen

Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia

Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).

1 finding from 1 review

Lower vs higher cumulative dose dexamethasone regimen

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).

1 finding from 1 review

Later vs earlier initiation of dexamethasone therapy

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).

1 finding from 1 review

Later vs earlier initiation of dexamethasone therapy

Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia

Later showed no clear difference in death or cerebral palsy at 1 to 3 years compared with earlier initiation of dexamethasone therapy (low certainty).

1 finding from 1 review

Later vs earlier initiation of dexamethasone therapy

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

Later showed no clear difference in death or abnormal neurodevelopmental outcome (various definitions) compared with earlier initiation of dexamethasone therapy (low certainty).

1 finding from 1 review

Pulse vs continuous dexamethasone therapy

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).

1 finding from 1 review

Pulse vs continuous dexamethasone therapy

Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia

It is very uncertain whether pulse changes death or abnormal neurodevelopmental outcome (various definitions) compared with continuous dexamethasone therapy (very low certainty).

1 finding from 1 review

Individual tailored vs continuous tapered dexamethasone regimen

Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia

Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).

1 finding from 1 review